#semaglutide
articles
Danish Study: 49% Stop Wegovy Within a Year, One in Four Restart
A nationwide Danish cohort finds high first-year semaglutide discontinuation, driven partly by cost and side effects, wi...
GLP-1 Drugs Are Moving Far Beyond Weight Loss — and Rewriting Chronic Disease Treatment
New trial data link semaglutide and tirzepatide to improvements in sleep apnea, kidney, liver and heart outcomes, recast...
Why Splitting a GLP-1 Pill to Microdose Is Unsafe
Cutting oral GLP-1 tablets destroys the SNAC delivery system that protects the drug in the stomach, leading to inconsist...
A Patient's Guide to GLP-1 Side Effects: From GI Upset to Rare Eye Risks
GLP-1 drugs are widely prescribed, but patients should understand the range of reported side effects — from common nause...
Novo Nordisk's Wegovy Pill Heads to Germany as Shares Slip on Pipeline Setback
Oral Wegovy is coming to Germany, but a CagriSema trial setback and modest pill sales tempered Novo Nordisk's guidance r...
Trial Finds Ozempic, Wegovy Drug Semaglutide Cuts Heavy Drinking in Alcohol Use Disorder
A 50-patient University of Colorado trial found oral semaglutide reduced heavy drinking and cravings, a step toward the ...
Anvisa Approves Five New Semaglutide Pens, Heating Up Brazil's R$5.6 Billion Weight-Loss Drug War
Brazil's health regulator cleared five additional semaglutide pens from Sandoz, Sun Pharma, Ranbaxy, and Brainfarma, sha...